Close menu




December 9th, 2020 | 11:00 CET

JinkoSolar, Scottie Resources, Palantir - Buying the future!

  • Investments
Photo credits: Scottie Resources

Comparing the figures of companies with their stock market valuation at the moment could make you dizzy. Particularly in the future topics of hydrogen, photovoltaics or data analysis, market capitalizations are five to six years ahead. What is important here is an innovative business model, growth and above all, a dominant market position.

time to read: 3 minutes | Author: Stefan Feulner
ISIN: CA81012R1064 , US47759T1007 , US69608A1088

Table of contents:


    The Golden Triangle

    With gold mines, of course, the first-class location of the mines and the high degree of mineralization are added to this. Here the Canadian gold exploration Company Scottie Resources has hit the bull's eye. Scottie Resources' projects are located in prime locations in the so-called "Golden Triangle". The Golden Triangle in British Columbia is one of the most productive mineralization areas in the world and is world-renowned for its rich deposits. The Canadians own more than 25,000 hectares in total. The claims also include a 100% interest in the high grade, formerly producing Scottie Gold Mine and Bow Properties.

    Sensational results in the "Blueberry Zone"

    Yesterday, Scottie Resources' management reported superior assay results for the Blueberry Zone of the Bow property. Bow is located just 2 kilometers northeast of the Scottie Mine. Also, a new direction of mineralization has been identified that is hostile to the historic Blueberry vein target. The intersection of several high-grade intercepts along the strike (including 22.3 grams per tonne gold over 6.1 metres) defines an intense mineralized line running north-south. This new target remains open along the strike and at depth, with numerous high-grade grab samples defining a zone with a strike length above 800 metres.

    Full program next year

    Scottie Resources CEO Bradley Rourke commented enthusiastically on the results: "Fantastic drill results in an ideal location. This new Blueberry trend is a near-surface target, literally situated on a road. The grades and widths of these results get us extremely excited about the economic potential of the area. Bolstered by the high-grade grab samples from this year, drilling in 2021 will see us aggressively step out along this new trend to establish the full extent of this remarkably large and high-grade system."**

    Prestige order drives price jump

    Palantir Technologies, a US-based provider of software and services related to the analysis of large amounts of data, has once again secured a strong new partner in the public sector. A three-year contract with a total value of USD 44.4 million has been signed with none other than the FDA, the Food and Drug Administration. In return, Palantir will provide the US Food and Drug Administration with its data integration and analysis services. Approximately 50% of Palantir's clients are currently private customers, with the other half of the contracts coming increasingly from government and intelligence circles. For example, Palantir has been commissioned by the US government to develop a system that will be used to track the production and distribution of Corona vaccines.

    Currently still irrevocable rating

    After reaching an all-time high of USD 33.00 last week, there was a brief, painful 30% correction to USD 21.00. The rebound, however, already came with the FDA notification. The Palantir share is currently trading at USD 30.00 again. Looking more closely at the figures for the third quarter, the current market value of USD 50.48 billion does not seem justified. Overall, however, Palantir is an absolute acquisition machine. The growth story is on track. Although the Americans still have to prove their stock market valuation, which is far too high at the moment, they are the undisputed market leader in the future topics of data analysis and artificial intelligence.

    Figures at last

    Investors had had to wait a long time for the quarterly figures of the Chinese photovoltaic manufacturer JinkoSolar. JinkoSolar could not report a real bang, but rather relatively stable results. So the Chinese have thus been able to expand their business further. Deliveries in the third quarter of the 2020 financial year reached almost 5.12 megawatts (MW), an increase of 53.8 % on the same period of the previous year. In the same period of the 2020 fiscal year, Company sales rose by 17.2%year-on-year to a total of USD 1.29 billion, thus meeting the upper estimates of analysts.

    Margins weak

    The development of the operating margin was less pleasing. At 6.1%, it was significantly lower than in the same period of the previous year. In September 2019, it was still at 8.5%. The net result was a profit of a meager USD 1.0 million. Although management is aiming for a global market share of 15% by 2021, the share initially went for a dive, but yesterday it was able to revise its initial losses during the day. The support zone at USD 60.00 is significant and should be maintained. In the long term, the story is on track.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by André Will-Laudien on May 10th, 2022 | 11:54 CEST

    GreenTech stocks are on the rise! Buy now: BASF, Meta Materials, Nordex, Siemens Energy

    • GreenTech
    • Technology
    • Investments

    The distortions on the capital markets can hardly be topped at the moment. The nickel price has risen by 300%, only to drop by 70% again. And all this in only 48 hours. There are countless examples in the current stock market environment that are historically unparalleled. In just 2 months, the Bund Future fell from 178 to 151, a loss of 16% in the 10-year Bund. In parallel, the capital market interest rate rose from minus 0.45% to a whopping plus 1.15%. So interest rates are back, inflation is spreading, and supply deficits continue to fuel the underlying stagflation scenario! One major trend should bounce back after the end of the many corrections: GreenTech! Here is a selection of interesting stocks.

    Read

    Commented by Carsten Mainitz on May 10th, 2022 | 10:39 CEST

    Zalando, Aspermont, SAP - Corona and back, the stock rebound is coming!

    • Digitization
    • Investments
    • Technology

    What would society and the economy look like without digitization? The Internet, software and smartphones have become a matter of everyday life and form the basis for communication and interaction. Corona has been an accelerator in many ways. On the other hand, pandemics and war clearly show us the limits of supposedly predictable growth with scarcity prices and supply chain disruptions. At a reduced price level, it is worth looking at "digitization stocks" that offer good opportunities.

    Read

    Commented by Juliane Zielonka on May 5th, 2022 | 12:57 CEST

    Bayer, NervGen, Adler Group - Pharma and Real Estate, management in focus

    • Biotechnology
    • Pharma
    • Investments

    Corporate giant Bayer is collaborating with Charité Berlin to cure genetic diseases in the future. A paradox? Big Pharma thrives on alleviating symptoms but not curing diseases. Things will soon look different. The biotech company NervGen is also dedicated to curing diseases. The approach here: reverse degenerative nerve conditions through self-healing. Specifically, this means helping individuals with paraplegia who are wheelchair-bound reconnect their neural pathways. The Company is in the clinical trials phase and was started by a co-founder who witnessed a dramatic accident. One cannot speak of an accident at the real estate company Adler Group. Four board members have resigned after auditor KPMG refused to give its OK for the annual financial statements. Can management regain the confidence of shareholders?

    Read